Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, February 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 129 articles:
HTML format


 

Single Articles

  1. MATOS J, Mussetto I, Podesta R, Schettini D, et al
    Bladder cancer presenting with acrometastases: a different cause of foot pain.
    Skeletal Radiol. 2018 Feb 1. pii: 10.1007/s00256-018-2888.
    Abstract    

    Abstract available

  2. TANIMOTO R, Saika T, Ebara S, Kobayashi Y, et al
    Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    World J Urol. 2018 Jan 31. pii: 10.1007/s00345-018-2196.
    Abstract    

    Abstract available

  3. TAN YG, Eu E, Lau Kam On W, Huang HH, et al
    Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer.
    Asian J Urol. 2017;4:239-246.
    Abstract    

    Abstract available

  4. YANG C, Yuan W, Yang X, Li P, et al
    Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression.
    Mol Cancer. 2018;17:19.
    Abstract    

    Abstract available

  5. COMPERAT E, Varinot J, Moroch J, Eymerit-Morin C, et al
    A practical guide to bladder cancer pathology.
    Nat Rev Urol. 2018 Jan 31. pii: nrurol.2018.2. doi: 10.1038/nrurol.2018.
    Abstract    

    Abstract available

  6. BIZHANI F, Hashemi M, Danesh H, Nouralizadeh A, et al
    Association between single nucleotide polymorphisms in the PI3K/AKT/mTOR pathway and bladder cancer risk in a sample of Iranian population.
    EXCLI J. 2018;17:3-13.
    Abstract    

    Abstract available

  7. CHRISTENSEN E, Nordentoft I, Vang S, Birkenkamp-Demtroder K, et al
    Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients.
    Sci Rep. 2018;8:1917.
    Abstract    

    Abstract available

  8. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Activity of Class I-IV Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase in Bladder Cancer Cells.
    Cancer Invest. 2018 Jan 30:1-7. doi: 10.1080/07357907.2017.1422511.
    Abstract    

    Abstract available

  9. BUSS JH, Begnini KR, Bender CB, Pohlmann AR, et al
    Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer.
    Front Pharmacol. 2018;8:977.
    Abstract    

    Abstract available

  10. SWEENEY SK, Luo Y, O'Donnell MA, Assouline JG, et al
    Peptide-Mediated Targeting Mesoporous Silica Nanoparticles: A Novel Tool for Fighting Bladder Cancer.
    J Biomed Nanotechnol. 2017;13:232-42.
    Abstract    

    Abstract available

  11. HAN Y, Jin X, Zhou H, Liu B, et al
    Identification of key genes associated with bladder cancer using gene expression profiles.
    Oncol Lett. 2018;15:297-303.
    Abstract    

    Abstract available

  12. JIANG K, Chen H, Tang K, Guan W, et al
    Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway.
    Oncol Lett. 2018;15:167-174.
    Abstract    

    Abstract available

  13. COLIN R, Grzebyk M, Wild P, Hedelin G, et al
    Bladder cancer and occupational exposure to metalworking fluid mist: a counter-matched case-control study in French steel-producing factories.
    Occup Environ Med. 2018 Jan 26. pii: oemed-2017-104666.
    Abstract    

    Abstract available

  14. HANG JF, Pan CC
    Response to: Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma: author reply.
    Pathology. 2017;49:562-563.
    Abstract    

    Abstract available

  15. REIS H, Niedworok C, Szarvas T
    Response to: Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma.
    Pathology. 2017;49:561-562.
    Abstract    



  16. WINDER M, Vesela R, Aronsson P, Patel B, et al
    Autonomic Receptor-mediated Regulation of Production and Release of Nitric Oxide in Normal and Malignant Human Urothelial Cells.
    Basic Clin Pharmacol Toxicol. 2017;121:257-265.
    Abstract    

    Abstract available

  17. BELLMUNT J, Kerst JM, Vazquez F, Morales-Barrera R, et al
    A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
    Ann Oncol. 2017;28:1517-1522.
    Abstract    

    Abstract available

  18. LI X, Wang W, Zhu G, He W, et al
    Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: a meta-analysis of 9498 patients.
    Oncotarget. 2017;9:2782-2796.
    Abstract    

    Abstract available

  19. WACH S, Weigelt K, Michalke B, Lieb V, et al
    Diagnostic potential of major and trace elements in the serum of bladder cancer patients.
    J Trace Elem Med Biol. 2018;46:150-155.
    Abstract    

    Abstract available

  20. CATTRINI C, Boccardo F
    Atezolizumab and bladder cancer: facing a complex disease.
    Lancet. 2018;391:305-306.
    Abstract    



  21. WANG W, Li C, Chen Y, Teng L, et al
    Increased expression of GGN promotes tumorigenesis in bladder cancer and is correlated with poor prognosis.
    Gene. 2018 Feb 2. pii: S0378-1119(18)30127-6. doi: 10.1016/j.gene.2018.
    Abstract    

    Abstract available

  22. JOBCZYK M, Pikala M, Rozanski W, Maniecka-Bryla I, et al
    Years of life lost due to bladder cancer among the inhabitants of Poland in the years 2000 to 2014.
    Cent European J Urol. 2017;70:338-343.
    Abstract    

    Abstract available

  23. WU K, Tan MY, Jiang JT, Mu XY, et al
    Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy.
    Clin Immunol. 2018 Feb 1. pii: S1521-6616(17)30473.
    Abstract    

    Abstract available

  24. LIN Y, Wang Y, Wu Q, Jin H, et al
    Association between obesity and bladder cancer recurrence: A meta-analysis.
    Clin Chim Acta. 2018;480:41-46.
    Abstract    

    Abstract available

  25. MASSARI F, Di Nunno V, Cubelli M, Santoni M, et al
    Immune checkpoint inhibitors for metastatic bladder cancer.
    Cancer Treat Rev. 2018;64:11-20.
    Abstract    

    Abstract available

  26. XU T, Yin J, Chen S, Zhang D, et al
    Elevated 8-oxo-7,8-dihydro-2'-deoxyguanosine in genome of T24 bladder cancer cells induced by halobenzoquinones.
    J Environ Sci (China). 2018;63:133-139.
    Abstract    

    Abstract available

  27. ARORA HC, Fascelli M, Zhang JH, Isharwal S, et al
    Kidney, Ureteral, and Bladder Cancer: A Primer for the Internist.
    Med Clin North Am. 2018;102:231-249.
    Abstract    

    Abstract available

  28. SAYYID RK, Sayyid AK, Klaassen Z, Hersey K, et al
    Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.
    Can Urol Assoc J. 2018 Feb 6. pii: cuaj.4922. doi: 10.5489/cuaj.4922.
    Abstract    

    Abstract available

  29. ALIVAND M, Soufi RT, Madani AH, Esmaeili SN, et al
    Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
    Bratisl Lek Listy. 2018;119:12-16.
    Abstract    

    Abstract available

  30. THOMA C
    Bladder cancer: Improving NMIBC risk stratification.
    Nat Rev Urol. 2018 Feb 6. pii: nrurol.2018.13. doi: 10.1038/nrurol.2018.
    Abstract    



  31. YANG YL, Li MY, Liu L, Wang L, et al
    Perceived stress and its associated demographic-clinical characteristics and positive expectations among Chinese cervical, kidney, and bladder cancer patients.
    Support Care Cancer. 2018 Feb 5. pii: 10.1007/s00520-018-4081.
    Abstract    

    Abstract available

  32. LI C, Zeng X, Liu Z, Li F, et al
    BDNF VAL66MET Polymorphism Elevates the Risk of Bladder Cancer via MiRNA-146b in Micro-Vehicles.
    Cell Physiol Biochem. 2018;45:366-377.
    Abstract    

    Abstract available

  33. AGHAMOHAMMADI D, Gargari RM, Fakhari S, Bilehjani E, et al
    Classic versus Inguinal Approach for Obturator Nerve Block in Transurethral Resection of Bladder Cancer under Spinal Anesthesia: A Randomized Controlled Trial.
    Iran J Med Sci. 2018;43:75-80.
    Abstract    

    Abstract available

  34. ROH YG, Mun MH, Jeong MS, Kim WT, et al
    Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1.
    BMB Rep. 2018 Feb 5. pii: 4050.
    Abstract    

    Abstract available

  35. PRESLER M, Wojtczyk-Miaskowska A, Schlichtholz B, Kaluzny A, et al
    Increased expression of the gene encoding stearoyl-CoA desaturase 1 in human bladder cancer.
    Mol Cell Biochem. 2018 Feb 2. pii: 10.1007/s11010-018-3306.
    Abstract    

    Abstract available

  36. ADAMIETZ IA
    [Complications instead of improved survival and local freedom from recurrence after early radical cystectomy in muscle-invasive bladder cancer compared to multimodal maintenance therapy].
    Strahlenther Onkol. 2018 Feb 2. pii: 10.1007/s00066-018-1274.
    Abstract    



  37. SCHROECK FR, Smith N, Shelton JB
    Implementing risk-aligned bladder cancer surveillance care.
    Urol Oncol. 2018 Jan 26. pii: S1078-1439(17)30645.
    Abstract    

    Abstract available

  38. GUO CC, Al-Ahmadie HA, Flaig TW, Kamat AM, et al
    Contribution of bladder cancer pathology assessment in planning clinical trials.
    Urol Oncol. 2018 Jan 29. pii: S1078-1439(18)30001.
    Abstract    

    Abstract available

  39. GODWIN JL, Hoffman-Censits J, Plimack E
    Recent developments in the treatment of advanced bladder cancer.
    Urol Oncol. 2018 Jan 26. pii: S1078-1439(17)30647.
    Abstract    

    Abstract available

  40. HUPE MC, Vahlensieck W, Ozimek T, Struck JP, et al
    Diarrhea and flatulence are major bowel disorders after radical cystectomy: Results from a cross-sectional study in bladder cancer patients.
    Urol Oncol. 2018 Jan 21. pii: S1078-1439(17)30643.
    Abstract    

    Abstract available

  41. KLAASSEN Z, Goldberg H, Chandrasekar T, Arora K, et al
    Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis.
    Clin Genitourin Cancer. 2018 Jan 5. pii: S1558-7673(18)30004.
    Abstract    

    Abstract available

  42. KILTIE AE, Southby R, LeMonnier K, Binnee J, et al
    High Levels of Patient Satisfaction in Joint Uro-oncology Clinics to Assist Patient Choice in Early Prostate Cancer and Muscle-invasive Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2018 Jan 25. pii: S0936-6555(18)30006.
    Abstract    



  43. LIAO G, Chen F, Zhong J, Jiang X, et al
    MicroRNA539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF1R.
    Mol Med Rep. 2018 Jan 25. doi: 10.3892/mmr.2018.8497.
    Abstract    

    Abstract available

  44. RUTHERFORD C, Patel MI, Tait MA, Smith DP, et al
    Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review.
    Support Care Cancer. 2018 Feb 1. pii: 10.1007/s00520-018-4058.
    Abstract    

    Abstract available

  45. RAZIK A, Das CJ, Sharma S, Seth A, et al
    Diagnostic performance of diffusion-weighted MR imaging at 3.0 T in predicting muscle invasion in urinary bladder cancer: utility of evaluating the morphology of the reactive tumor stalk.
    Abdom Radiol (NY). 2018 Feb 1. pii: 10.1007/s00261-018-1458.
    Abstract    

    Abstract available

  46. ASAI S, Miura N, Sawada Y, Noda T, et al
    Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells.
    Oncol Lett. 2018;15:522-527.
    Abstract    

    Abstract available

  47. WU H, Wang X, Mo N, Zhang L, et al
    B7-homolog 4 promotes epithelial-mesenchymal transition and invasion of bladder cancer cells via activation of nuclear factor-kappaB.
    Oncol Res. 2018 Feb 1. doi: 10.3727/096504018X15172227703244.
    Abstract    

    Abstract available

  48. LI H, Liu L, Shi Q, Stemmer A, et al
    Bladder cancer: detection and image quality compared among iShim, RESOLVE, and ss-EPI diffusion-weighted MR imaging with high b value at 3.0 T MRI.
    Medicine (Baltimore). 2017;96:e9292.
    Abstract    

    Abstract available

  49. QIU X, Cao K, Lin T, Chen W, et al
    Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation.
    Int J Nanomedicine. 2017;12:7365-7374.
    Abstract    

    Abstract available

  50. FARLEY A, Koshiaris C, Oke J, Ryan R, et al
    Physician Support of Smoking Cessation After Diagnosis of Lung, Bladder, or Upper Aerodigestive Tract Cancer.
    Ann Fam Med. 2017;15:443-450.
    Abstract    

    Abstract available

  51. HODGSON A, Xu B, Satkunasivam R, Downes MR, et al
    Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder.
    J Clin Pathol. 2018;71:154-160.
    Abstract    

    Abstract available

  52. KWON JE, Cho NH, Choi YJ, Lim SD, et al
    Level of mitoses in non-muscle invasive papillary urothelial carcinomas (pTa and pT1) at initial bladder biopsy is a simple and powerful predictor of clinical outcome: a multi-center study in South Korea.
    Diagn Pathol. 2017;12:54.
    Abstract    

    Abstract available

  53. VIRK RK, Abro S, de Ubago JMM, Pambuccian SE, et al
    The value of the UroVysion(R) FISH assay in the risk-stratification of patients with "atypical urothelial cells" in urinary cytology specimens.
    Diagn Cytopathol. 2017;45:481-500.
    Abstract    

    Abstract available

  54. GUO H, Xu W, Chen J, Yan L, et al
    Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma.
    J Control Release. 2017;259:136-148.
    Abstract    

    Abstract available

  55. KIM JK, Cho MC, Ku JH, Paick JS, et al
    Preperitoneal placement of an inflatable penile prosthesis reservoir for postoperative erectile dysfunction after radical cystoprostatectomy with orthotopic neobladder.
    Investig Clin Urol. 2016;57:364-6.
    Abstract    

    Abstract available

  56. MIJNES J, Veeck J, Gaisa NT, Burghardt E, et al
    Promoter methylation of DNA damage repair (DDR) genes in human tumor entities: RBBP8/CtIP is almost exclusively methylated in bladder cancer.
    Clin Epigenetics. 2018;10:15.
    Abstract    

    Abstract available

  57. WANG M, Guo C, Wang L, Luo G, et al
    Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription.
    Cell Death Dis. 2018;9:238.
    Abstract    

    Abstract available

  58. SU F, He W, Chen C, Liu M, et al
    The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1.
    Cell Death Dis. 2018;9:233.
    Abstract    

    Abstract available

  59. HIROBE M, Tanaka T, Shindo T, Ichihara K, et al
    Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan.
    Int J Clin Oncol. 2018 Feb 13. pii: 10.1007/s10147-018-1245.
    Abstract    

    Abstract available

  60. HUANG XX, Wang RX, Lin Q, Chen W, et al
    Inhibitory effects of 2-methoxyestradiol on cell growth and invasion in human bladder cancer T-24 cells.
    Pharmazie. 2017;72:87-90.
    Abstract    

    Abstract available

  61. ZHOU YM, Feng X, Zhou BC, Fan YF, et al
    Evaluation of therapeutic effects of (125)I particles brachytherapy for recurrent bladder cancer.
    Oncol Lett. 2018;15:3453-3457.
    Abstract    

    Abstract available

  62. XIANG X, Huang J, Mo W, Jiang L, et al
    Long non-coding RNA cartilage injury-related promotes malignancy in bladder cancer.
    Oncol Lett. 2018;15:3049-3055.
    Abstract    

    Abstract available

  63. LI Z, Zhang TB, Jia DH, Sun WQ, et al
    Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling.
    Oncol Lett. 2018;15:2619-2624.
    Abstract    

    Abstract available

  64. MA Z, Xue S, Zeng B, Qiu D, et al
    lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27.
    Oncol Lett. 2018;15:1924-1930.
    Abstract    

    Abstract available

  65. MEMON AA, Gilliver SC, Borre M, Sundquist J, et al
    Soluble HER3 predicts survival in bladder cancer patients.
    Oncol Lett. 2018;15:1783-1788.
    Abstract    

    Abstract available

  66. KELSEY R
    Bladder cancer: BBN mouse model mimics human MIBC.
    Nat Rev Urol. 2018 Feb 13. pii: nrurol.2018.17. doi: 10.1038/nrurol.2018.
    Abstract    



  67. XU M, Li J, Wang X, Meng S, et al
    MiR-22 suppresses epithelial-mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop.
    Cell Death Dis. 2018;9:209.
    Abstract    

    Abstract available

  68. PAQUETTE M, Beaudoin S, Tremblay MA, Jean S, et al
    NLS-cholic acid conjugation to IL-5Ralpha-specific antibody improves cellular accumulation and in vivo tumor-targeting properties in a bladder cancer model.
    Bioconjug Chem. 2018 Feb 13. doi: 10.1021/acs.bioconjchem.8b00077.
    Abstract    

    Abstract available

  69. MESSING EM
    Molecular Landscape of Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2018;4:131-132.
    Abstract    



  70. GARG T, Connors JN, Ladd IG, Bogaczyk TL, et al
    Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2018;4:121-128.
    Abstract    

    Abstract available

  71. FARBER NJ, Faiena I, Dombrovskiy V, Tabakin AL, et al
    Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer.
    Bladder Cancer. 2018;4:113-120.
    Abstract    

    Abstract available

  72. WESTHOFF E, Witjes JA, Fleshner NE, Lerner SP, et al
    Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.
    Bladder Cancer. 2018;4:91-112.
    Abstract    

    Abstract available

  73. TAMURA S, Wang Y, Veeneman B, Hovelson D, et al
    Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.
    Bladder Cancer. 2018;4:77-90.
    Abstract    

    Abstract available

  74. WALKER M, Doiron RC, French SD, Brennan K, et al
    Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers.
    Bladder Cancer. 2018;4:49-65.
    Abstract    

    Abstract available

  75. LI R, Metcalfe M, Kukreja J, Navai N, et al
    Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review.
    Bladder Cancer. 2018;4:31-40.
    Abstract    

    Abstract available

  76. TODENHOFER T, Struss WJ, Seiler R, Wyatt AW, et al
    Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.
    Bladder Cancer. 2018;4:19-29.
    Abstract    

    Abstract available

  77. ABBOSH PH, Plimack ER
    Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer.
    Bladder Cancer. 2018;4:9-18.
    Abstract    



  78. SHERIF A, Winerdal M, Winqvist O
    Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2018;4:1-7.
    Abstract    

    Abstract available

  79. MUKHERJEE N, Svatek RS, Mansour AM
    Role of immunotherapy in bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Urol Oncol. 2018 Feb 8. pii: S1078-1439(17)30649.
    Abstract    

    Abstract available

  80. MARCHIONI M, Nazzani S, Preisser F, Bandini M, et al
    Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.
    Expert Rev Anticancer Ther. 2018 Feb 15:1-11. doi: 10.1080/14737140.2018.1439744
    Abstract    

    Abstract available

  81. LI WL, Ji GH, Zhang XZ, Yu HY, et al
    [The influence and mechanisms of purple sweet potato anthocyanins on the growth of bladder cancer BIU87 cell].
    Zhonghua Yi Xue Za Zhi. 2018;98:457-459.
    Abstract    

    Abstract available

  82. ZHANG S, Wang Y, Bondaruk J, Majewski T, et al
    Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.
    Eur Urol Focus. 2018 Feb 7. pii: S2405-4569(18)30018.
    Abstract    

    Abstract available

  83. FANG CW, Liao CH, Wu SC, Muo CH, et al
    Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study.
    World J Urol. 2018 Feb 9. pii: 10.1007/s00345-018-2216.
    Abstract    

    Abstract available

  84. ALLIONE A, Pardini B, Viberti C, Oderda M, et al
    The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer.
    Urol Oncol. 2018 Feb 6. pii: S1078-1439(18)30006.
    Abstract    

    Abstract available

  85. RIVERO GUERRA A, Fernandez Aparicio T, Barcelo Bayonas I, Pardo Martinez A, et al
    Outpatient Holmium laser fulguration: A safe procedure for treatment of recurrence of nonmuscle invasive bladder cancer.
    Actas Urol Esp. 2018 Feb 5. pii: S0210-4806(18)30003.
    Abstract    

    Abstract available

  86. LIU X, Li S, Li Y, Cheng B, et al
    Puerarin inhibits proliferation and induces apoptosis by up-regulation of miR-16 in bladder cancer cell line T24.
    Oncol Res. 2018 Feb 8. doi: 10.3727/096504018X15178736525106.
    Abstract    

    Abstract available

  87. CORMIO L, Mancini V, Calo B, Selvaggio O, et al
    Asymptomatic solitary bladder plasmocytoma: A case report and literature review.
    Medicine (Baltimore). 2017;96:e9347.
    Abstract    

    Abstract available

  88. FEDUS T, Ras R, Ksiazek M, Filipowska J, et al
    Primary vaginal squamous cell carcinoma with bladder involvement in uterine prolapsed patient: Case report.
    Medicine (Baltimore). 2017;96:e8993.
    Abstract    

    Abstract available

  89. EL BOTE H, Atik S, Fares R, Hage E, et al
    [Inverted papilloma of the bladder: a rare benign tumor: a case report].
    Pan Afr Med J. 2017;26:204.
    Abstract    



  90. KIM HC, Park HP, Lee J, Jeong MH, et al
    Sevoflurane vs. propofol in post-operative catheter-related bladder discomfort: a prospective randomized study.
    Acta Anaesthesiol Scand. 2017;61:773-780.
    Abstract    

    Abstract available

  91. MOHANTY BD, Mohanty S, Hussain Y, Padmaraju C, et al
    Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge.
    Future Cardiol. 2017;13:247-257.
    Abstract    

    Abstract available

  92. MANIG L, Janssen S, Schild SE, Rades D, et al
    A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder.
    In Vivo. 2017;31:435-438.
    Abstract    

    Abstract available

  93. WU GX, Nelson RA, Kim JY, Raz DJ, et al
    Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
    Clin Lung Cancer. 2017 Mar 2. pii: S1525-7304(17)30050.
    Abstract    

    Abstract available

  94. DUTTA R, Yoon R, Patel RM, Spradling K, et al
    Clinical Comparison of Conventional and Mobile Endockscope Videocystoscopy Using an Air or Fluid Medium.
    J Endourol. 2017;31:593-597.
    Abstract    

    Abstract available

  95. KOESTLER DC, Usset J, Christensen BC, Marsit CJ, et al
    DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes.
    Cancer Epidemiol Biomarkers Prev. 2017;26:328-338.
    Abstract    

    Abstract available

  96. FREMEREY J, Balzer S, Brozou T, Schaper J, et al
    Embryonal rhabdomyosarcoma in a patient with a heterozygous frameshift variant in the DICER1 gene and additional manifestations of the DICER1 syndrome.
    Fam Cancer. 2017;16:401-405.
    Abstract    

    Abstract available

  97. CHEN QN, Wei CC, Wang ZX, Sun M, et al
    Long non-coding RNAs in anti-cancer drug resistance.
    Oncotarget. 2017;8:1925-1936.
    Abstract    

    Abstract available

  98. SHIBA S, Wakatsuki M, Kato S, Ohno T, et al
    Carbon-ion radiotherapy for locally advanced cervical cancer with bladder invasion.
    J Radiat Res. 2016.
    Abstract    

    Abstract available

  99. LIN T, Zhao X, Zhao S, Yu H, et al
    O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia.
    Theranostics. 2018;8:990-1004.
    Abstract    

    Abstract available

  100. MAHE M, Dufour F, Neyret-Kahn H, Moreno-Vega A, et al
    An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.
    EMBO Mol Med. 2018 Feb 20. pii: emmm.201708163. doi: 10.15252/emmm.201708163.
    Abstract    

    Abstract available

  101. DU Y, Wang L, Wang W, Guo T, et al
    Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer.
    J Biomed Nanotechnol. 2018;14:161-167.
    Abstract    

    Abstract available

  102. SUN X, Zhang T, Deng Q, Zhou Q, et al
    Benzidine Induces Epithelial-Mesenchymal Transition of Human Bladder Cancer Cells through Activation of ERK5 Pathway.
    Mol Cells. 2018 Feb 21. pii: molcells.2018.2113.
    Abstract    

    Abstract available

  103. LIU Z, Ye Y, Li X, Guo S, et al
    The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer.
    World J Urol. 2018 Feb 19. pii: 10.1007/s00345-018-2199.
    Abstract    

    Abstract available

  104. FLETCHER SA, Gild P, Cole AP, Vetterlein MW, et al
    The effect of treatment at minority-serving hospitals on outcomes for bladder cancer.
    Urol Oncol. 2018 Feb 14. pii: S1078-1439(18)30010.
    Abstract    

    Abstract available

  105. CEYLAN C, Yahsi S, Dogan S, OztUrk E, et al
    Emphasis of FAS/FASL gene polymorphism in patients with non-muscle invasive bladder cancer.
    Ir J Med Sci. 2018 Feb 16. pii: 10.1007/s11845-018-1764.
    Abstract    

    Abstract available

  106. DECAESTECKER K, Lumen N, Van Camp C, Oosterlinck W, et al
    Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
    Acta Clin Belg. 2018 Feb 16:1-4. doi: 10.1080/17843286.2018.1440706.
    Abstract    

    Abstract available

  107. BHANDARI P, Novikova G, Goergen CJ, Irudayaraj J, et al
    Ultrasound beam steering of oxygen nanobubbles for enhanced bladder cancer therapy.
    Sci Rep. 2018;8:3112.
    Abstract    

    Abstract available

  108. HU C, Liu Y, Lin Y, Liang JK, et al
    Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer.
    Cell Death Dis. 2018;9:274.
    Abstract    

    Abstract available

  109. CHEN WS, Townsend JP, Yu JB
    Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets.
    Int J Radiat Oncol Biol Phys. 2017;98:8-10.
    Abstract    



  110. GERAILY G, Sharafi N, Shirazi A, Esfehani M, et al
    Comparison of beam hardening effect of physical and enhanced dynamic wedges at bladder inhomogeneity using EBT3 film dosimeter.
    J Cancer Res Ther. 2017;13:97-101.
    Abstract    

    Abstract available

  111. LEWIS S, Murthy V, Mahantshetty U, Shrivastava SK, et al
    Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?
    Technol Cancer Res Treat. 2017;16:382-387.
    Abstract    

    Abstract available

  112. CHO YM, Hasumura M, Imai T, Takami S, et al
    Horseradish extract promotes urinary bladder carcinogenesis when administered to F344 rats in drinking water.
    J Appl Toxicol. 2017;37:853-862.
    Abstract    

    Abstract available

  113. BAO Z, Zhang W, Dong D
    A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Oncotarget. 2017;8:10485-10497.
    Abstract    

    Abstract available

  114. HEERS H, Gut JM, Hegele A, Hofmann R, et al
    Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose.
    Anticancer Res. 2018;38:833-837.
    Abstract    

    Abstract available

  115. SPAHN M, Morlacco A, Boxler S, Joniau S, et al
    Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13818.
    Abstract    

    Abstract available

  116. SAKAGUCHI T, Yoshino H, Yonemori M, Miyamoto K, et al
    Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer.
    Br J Cancer. 2018 Feb 13. pii: bjc2017439. doi: 10.1038/bjc.2017.
    Abstract    

    Abstract available

  117. DAIZUMOTO K, Yoshimaru T, Matsushita Y, Fukawa T, et al
    A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer.
    Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-2528.
    Abstract    

    Abstract available

  118. JIANG G, Huang C, Li J, Huang H, et al
    Transcriptional and Posttranscriptional Upregulation of p27 Mediates Growth Inhibition of Isorhapontigenin (ISO) on Human Bladder Cancer Cells.
    Carcinogenesis. 2018 Feb 2. pii: 4834629. doi: 10.1093.
    Abstract    

    Abstract available

  119. WANG WJ, Li CF, Chu YY, Wang YH, et al
    Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Clin Cancer Res. 2017;23:503-513.
    Abstract    

    Abstract available

  120. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    Abstract    

    Abstract available

  121. COLLINS JW, Hosseini A, Adding C, Nyberg T, et al
    Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.
    Eur Urol. 2017;71:723-726.
    Abstract    

    Abstract available

  122. GAKIS G, Black PC, Bochner BH, Boorjian SA, et al
    Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
    Eur Urol. 2017;71:545-557.
    Abstract    

    Abstract available

  123. BABJUK M, Bohle A, Burger M, Capoun O, et al
    EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Eur Urol. 2017;71:447-461.
    Abstract    

    Abstract available

  124. EL-ACHKAR A, Kassouf W
    Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Eur Urol. 2018 Feb 14. pii: S0302-2838(18)30088.
    Abstract    



  125. LIU X, Cheng X, Liu X, He L, et al
    Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
    Int J Cancer. 2018 Feb 16. doi: 10.1002/ijc.31323.
    Abstract    

    Abstract available

  126. PULIDO M, Roubaud G, Cazeau AL, Mahammedi H, et al
    Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
    BMC Cancer. 2018;18:194.
    Abstract    

    Abstract available

  127. SEVERINO PF, Silva M, Carrascal M, Malagolini N, et al
    Oxidative damage and response to Bacillus Calmette-Guerin in bladder cancer cells expressing sialyltransferase ST3GAL1.
    BMC Cancer. 2018;18:198.
    Abstract    

    Abstract available

  128. SATHE A, Chalaud G, Oppolzer I, Wong KY, et al
    Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    PLoS One. 2018;13:e0190854.
    Abstract    

    Abstract available

  129. KIM M, Oh SJ, Kwak C, Kim HH, et al
    Psychometric validation study of the Korean version of the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index.
    PLoS One. 2018;13:e0190570.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;